Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Una Ryan is President, CEO and Member of the Board of Directors of AVANT Immunotherapeutics, Inc. Ryan joined AVANT as Vice President, Research and Chief Scientific Officer in May 1993. She is also research professor of medicine at the Whitaker Cardiovascular Institute of the Boston University School of Medicine. Prior to joining AVANT, Ryan was director of health sciences at Monsanto Company and research professor of surgery, medicine and cell biology at Washington University School of Medicine from 1990 to 1993. Ryan is a member of the governing body of the Biotechnology Industry Organization's (BIO) Emerging Companies Section and serves on the Board of BIO and the Massachusetts Biotechnology Council. Ryan is also a member of the board of associates at the Whitehead Institute for Biomedical Research and is currently a director of IQuum, Inc. In 2002, Ryan was awarded the Order of the British Empire for her services to research, development and promotion of biotechnology by Her Majesty, Queen Elizabeth the Second.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »